CyBeR Association in Relapsed/Refractory DLBCL

Exclusion Criteria

• •1. Person under guardianship or curatorship , or unable to understand the purpose of the study
• •2. Central nervous system or meningeal involvement
• •3. WHO performance status more than 2
• •4. Contraindication to any drug contained in the chemotherapy regimen
• •5. HIV disease, active hepatitis B or C
• •6. Any serious active disease or co-morbid medical condition
• •7. Any of the following laboratory abnormalities.
• •* Leucocyte count \< 3.0 x 109/L
• •* Platelet count \< 75 x 109/L
• •8. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
• •9. Pregnant or lactating females.
• •10. Prior history of malignancies, other than lymphoma, unless the patient has been free of the disease for ≥ 3 years. Exceptions include the following:
• •* Basal cell carcinoma of the skin.
• •* Squamous cell carcinoma of the skin.
• •* Carcinoma in situ of the cervix.
• •* Carcinoma in situ of the breast.
• •* Incidental histological finding of prostate cancer (TNM stage of T1a or T1b).
• •11. renal impairment with an estimated (modified dietin renal disease; MDRD) creatinine clearance \< 40 ml/min,
• •12. chronic liver disease or day-1 (AST/ALT )≥2.5 upper limit of normal (ULN), total bilirubin≥1.5 ULN,